Summary of Conference Call Notes Industry Overview - The focus is on the **innovative pharmaceutical industry** in China, particularly the progress of domestic companies in early-stage research compared to their Western counterparts [1] Key Points and Arguments - There is a **growing trend** of domestic innovative drugs catching up and potentially surpassing Western innovations in early research stages, as evidenced by recent business development (BD) activities [1] - Recent announcements from **China Biologic Products** and **Deqi Pharmaceuticals** regarding partnerships with **Sanofi** and **UCB** highlight the ongoing progress in the industry [1] - The **CD3/CD19 dual-target antibody** from Deqi is already in the early research phase and is being marketed internationally, indicating a significant advancement in the sector [1] - The upcoming **AACR** conference in April and the **ASCO** conference mid-year are expected to provide further insights and updates on the industry [1] - Despite potential fluctuations in BD optimism, the industry is expected to continue benefiting from ongoing BD contributions, reinforcing the growth potential of the sector [1] - The **global participation** of innovative drugs from China has been increasingly evident since 2025, suggesting a positive outlook for domestic new drugs in the mid-term [1] - The expectation is that domestic innovative drugs will enter a **harvest period** due to efficiency-driven competition, making it a promising investment opportunity [1] Additional Important Content - Recommendations for **high-certainty stocks** with relatively low BD disruption include: **Innovent Biologics**, **3SBio**, **Kangfang Biopharmaceuticals**, **Ying'en Biopharmaceuticals**, **Vila Biotech**, **Lepu Biopharma**, and **Kangnuo Pharmaceuticals** [2] - Attention is also drawn to new technology sectors such as **small nucleic acids**, with companies like **Frontier Biotech**, **Sunshine Nuohuo**, and upstream supply chain firms like **Aorite**, **Lanshan Technology**, **Nami Technology**, and **Jiuzhou Pharmaceutical** being highlighted [2]